Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: Clinical effectiveness and predictors of response.
Sign Up to like & getrecommendations! Published in 2020 at "European journal of endocrinology"
DOI: 10.1530/eje-20-0767
Abstract: BACKGROUND The treatment of acromegaly resistant to first generation somatostatin receptor ligands (SRLs) is often difficult. Pegvisomant and Pasireotide LAR are mostly used in these subset of patients, as second line therapies. Choice of the… read more here.
Keywords: pasireotide lar; acromegaly; pegvisomant pasireotide; second line ... See more keywords